Vaccine containing genetically-detoxified pertussis holotoxin
AssigneeConnaught Laboratories Limited
InventorsMichel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
Life of this patent
Estimating the term…
Abstract
A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.
Claims2
A vaccine against Bordetella pertussis, comprising an effective amount of an immmunoprotective genetically-detoxified mutant of pertussis holotoxin wherein at least one specific amino acid residue which contributes to pertussis toxin toxicity has been removed or replaced and at least one other immunoprotective pertussis antigen, and a physiologically-acceptable carrier therefor.
Dependencies are inferred from the claim text.